anaerobic dopamine (A-dopamine) / InBrain Pharma - LARVOL DELTA

DIVE-FOLLOW UP: Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine) (clinicaltrials.gov) - P1/2 | N=1 | Recruiting | Sponsor: University Hospital, Lille

New P1/2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference (GlobeNewswire) - "These long-term results confirm the excellent safety profile of the continuous intracerebroventricular infusion of A-dopamine in advanced parkinsonians refractory to L-dopa and also show a sustainable effect on motor control over time."

P1/2 data • Parkinson's Disease